CN115161275B - 一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 - Google Patents
一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 Download PDFInfo
- Publication number
- CN115161275B CN115161275B CN202210866662.1A CN202210866662A CN115161275B CN 115161275 B CN115161275 B CN 115161275B CN 202210866662 A CN202210866662 A CN 202210866662A CN 115161275 B CN115161275 B CN 115161275B
- Authority
- CN
- China
- Prior art keywords
- bovine
- decellularized
- matrix
- microsphere
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 75
- 239000004005 microsphere Substances 0.000 title claims abstract description 52
- 230000002500 effect on skin Effects 0.000 title claims abstract description 47
- 238000004113 cell culture Methods 0.000 title description 7
- 241000283690 Bos taurus Species 0.000 claims abstract description 76
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 30
- 210000004207 dermis Anatomy 0.000 claims abstract description 17
- 239000000839 emulsion Substances 0.000 claims abstract description 17
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 7
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 7
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 7
- 229940111202 pepsin Drugs 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 4
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 claims abstract description 4
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims abstract description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000010985 leather Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 4
- 239000012498 ultrapure water Substances 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 32
- 210000001185 bone marrow Anatomy 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 108090000695 Cytokines Proteins 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 4
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 abstract description 3
- 102100024270 Transcription factor SOX-2 Human genes 0.000 abstract description 3
- 238000004132 cross linking Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 abstract 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 31
- 239000012071 phase Substances 0.000 description 17
- 241000282465 Canis Species 0.000 description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
- C12N5/0075—General culture methods using substrates using microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种牛脱细胞真皮基质微球,它是将牛真皮进行脱细胞处理后,用胃蛋白酶消化为溶液状态,然后使用乳化交联法制备而成。本发明提供的微球具有较大的表面积和立体的三维结构,易于细胞粘附,能为细胞提供丰富的胞外基质环境,有利于细胞的存活和增殖。试验结果还表明,该微球能提高骨髓间充质干细胞干性相关基因如OCT4和SOX2的表达,促进细胞因子如TGF‑β、EGF、TSG‑6和VEGF的分泌,从而能增强细胞的分化潜能和免疫调节功能,提高其临床应用效果。
Description
技术领域
本发明涉及一种用于细胞三维培养的牛脱细胞真皮基质微球。
背景技术
微球可以为细胞提供三维培养的环境,相比于二维培养,三维培养具有许多不同的特征,如形态特征、增殖分化潜能、细胞-细胞与细胞周围基质的相互作用、信号转导等。目前,细胞治疗需要大量的细胞,二维培养所产生的细胞远远不能达到要求,为了克服这一缺点,三维微球培养应运而生。三维微球应有远大于二维培养的表面积,可以大规模扩增细胞。目前,微球一般使用人工合成高分子材料和天然高分子材料,主要有聚乳酸、聚乙二醇、明胶、胶原、葡聚糖和海藻酸盐等。乳化交联法可用于制作微球,乳化交联法制备油包水乳液液滴,将水相溶液加入油相溶液进行搅拌,形成液滴后加入交联剂,使水相溶液固化形成微球。制备微球的方法极其简单便捷,且能够实现微球的大量生产。
理想的生物活性材料的性质应与天然组织细胞外基质的结构和生物性质相似。脱细胞基质是通过去除组织或器官中的细胞组分制备的天然材料,保留组织或器官的三维结构和一些天然纤维组分,例如Ⅰ型胶原蛋白、Ⅲ型胶原蛋白、纤维连接蛋白、层粘连蛋白和糖胺聚糖等;脱细胞基质具有良好的生物活性、生物相容性和低免疫原性。目前,人们普遍使用胶原蛋白等材料进行细胞的三维培养,来模拟体内细胞外基质,但胶原蛋白毕竟只是细胞外基质的成分之一,它无法模拟复杂的细胞生长环境。己有的研究中,人们使用动物的皮肤、肝脏、心脏、软骨和小肠等组织器官制备成脱细胞基质。牛皮由于价格便宜、易获取、没有伦理和宗教约束等优势,被广泛用于脱细胞基质的制备。如今,已有多种脱细胞基质用于细胞的培养,但细胞通常只能在脱细胞基质的表面生长,很少有细胞能进入其内部,这使得直接用脱细胞基质培养细胞的有效面积大大减少,限制了脱细胞基质的使用。因此,使用脱细胞基质构建一种新的细胞培养生物材料是十分具有意义的。
间充质干细胞广泛应用于组织修复与各种疾病的治疗,近年来,有大量研究表明,间充质干细胞的治疗作用主要来自于其归巢作用和旁分泌作用。干性的提高有助于增强间充质干细胞的分化潜能,间充质干细胞分泌的细胞因子可以调节免疫系统,抑制细胞死亡和纤维化,刺激血管形成,并促进组织重塑。间充质干细胞生物活性并非一成不变的,它会随外界环境的影响而改变。
通过牛脱细胞真皮基质制备的微球,为间充质干细胞提供天然的体内细胞外基质三维环境,提高间充质干细胞分泌功能和干性,提高临床中间充质干细胞的治疗效果。
发明内容
本发明的目的是提供一种用于细胞三维培养的牛脱细胞真皮基质微球。
一种牛脱细胞真皮基质微球,其制备方法包括以下步骤:
(1)将牛皮去除表皮和脂肪组织后切成牛真皮小块,将牛真皮小块依次加入到碳酸钠溶液、NaCl溶液、SDS溶液中进行搅拌脱细胞处理,用水洗净后得到牛脱细胞真皮基质,然后将其冻干,粉碎,得到牛脱细胞真皮基质粉末;
(2)将牛脱细胞真皮基质粉末置于含有胃蛋白酶的乙酸溶液中消化24-48h,离心取上清液,用NaOH调节上清液pH至中性,得可溶性牛脱细胞真皮基质溶液;
(3)将乳化剂和矿物油混匀形成油相,将可溶性牛脱细胞真皮基质溶液加入到油相中,搅拌形成乳液,然后向乳液中加入戊二醛使可溶性牛脱细胞真皮基质固化,最后向乳液中加入异丙醇使乳液分层,离心取沉淀,依次用丙酮、异丙醇和超纯水清洗,置于PBS中浸泡过夜,去除PBS后即得到牛脱细胞真皮基质微球。
优选地,所述碳酸钠溶液的浓度为1-10%,所述NaCl溶液的浓度为0.5-5M,所述SDS溶液的浓度为0.2-2%。
优选地,所述胃蛋白酶在乙酸溶液中的浓度为0.5-5%。
优选地,所述乙酸溶液的浓度为0.1-1M。
优选地,所述乳化剂是span-80。
优选地,所述矿物油是液体石蜡。
优选地,所述乳化剂与矿物油的体积比为1:50-100。
所述的牛脱细胞真皮基质微球应用于细胞三维培养,尤其是间充质干细胞的三维培养,它具有较大的表面积和立体的三维结构,易于细胞粘附,能为细胞提供丰富的胞外基质环境,有利于细胞的存活和增殖。试验结果还表明,本发明提供的微球能提高骨髓间充质干细胞干性相关基因如OCT4和SOX2的表达,促进细胞因子如TGF-β、EGF、TSG-6和VEGF的分泌,从而能增强细胞的分化潜能和免疫调节功能,提高其临床应用效果。
本发明还具有安全无毒,细胞相容性好,微球结构稳定,原材料易得,生产成本低等优点,有广阔的应用前景。
更详细的技术方案参见具体实施例。
附图说明
图1是实施例中制备的牛脱细胞真皮基质的外观图;
图2是实施例中制备的牛脱细胞真皮基质溶液的外观图;
图3是实施例中制备的牛脱细胞真皮基质微球在光学显微镜下的状态图;
图4是实施例中制备的牛脱细胞真皮基质微球粒径分布图;
图5是实施例中犬骨髓间充质干细胞在牛脱细胞真皮基质微球上的生长状况;
图6是实施例中牛脱细胞真皮基质微球细胞毒性检测结果;
图7是实施例中牛脱细胞真皮基质微球活/死细胞检测结果;
图8是实施例中犬骨髓间充质干细胞干性基因mRNA相对表达量;
图9是实施例中犬骨髓间充质干细胞细胞因子ELISA检测结果。
具体实施方式
下面结合实施例,对本发明进行进一步说明。
实施例1
(1)牛脱细胞真皮基质的制备:
a:将牛皮去除表皮的脂肪组织后切成约为0.5cm×0.5cm×0.1cm的牛真皮小块,将20g牛真皮小块置于500mL 10%(w/w)碳酸钠溶液中用磁力搅拌器在转速200r/min下搅拌2h,用蒸馏水洗净后,放入500ml的1M NaCl溶液中用磁力搅拌器在转速200rpm下搅拌12h,用蒸馏水洗净后置于500mL 1%(w/w)十二烷基磺酸钠(SDS)溶液中,用磁力搅拌器在转速200r/min下搅拌6h,洗净后得到牛脱细胞真皮基质,其外观如图1所示;
b:使用冻干机将步骤a中得到的牛脱细胞真皮基质冻干48h,使用粉碎机在30000r/min的转速下,将冻干后的牛真皮脱细胞基质打碎成粉末;
(2)牛脱细胞真皮基质溶液的制备:
将(1)中制备的牛脱细胞真皮基质粉末置于500mL含有1%(w/w)胃蛋白酶的0.5M乙酸溶液中室温消化48h,然后3000r/min离心10min取上清液,向上清液中加入5M的NaOH溶液调节pH至7左右,其外观如图2所示;
(3)牛脱细胞真皮基质微球的制备:
向烧杯中加入1mL乳化剂span-80和50mL液体石蜡后混匀形成油相,置于搅拌器上,将(2)中的可溶性牛脱细胞真皮基质溶液加入油相中,室温下,200r/min搅拌1h形成水相/油相乳液。向乳液中加入200μL的5%戊二醛水溶液,搅拌1h,使牛脱细胞真皮基质固化。然后再向乳液中加入20mL异丙醇使油相和水相分层,3000r/min离心5min,去除上清液,将沉淀用丙酮、异丙醇和超纯水反复清洗3次后,置于PBS中浸泡过夜,去除PBS后得到牛脱细胞真皮基质微球。在光学显微镜下观察其外观如图3所示,使用ImageJ测量其粒径,使用Origin 2021进行分析粒径分布,如图4所示。
实施例2
(1)牛脱细胞真皮基质的制备:
a:将20g牛真皮小块置于500mL 5%碳酸钠溶液中用磁力搅拌器在转速200rpm下搅拌3h,用蒸馏水洗净后,放入500ml的2M NaCl溶液中用磁力搅拌器在转速200rpm下搅拌12h,用蒸馏水洗净后置于500mL 0.5%(w/w)十二烷基磺酸钠(SDS)溶液中,用磁力搅拌器在转速200rpm下搅拌12h,洗净后得到牛脱细胞真皮基质;
b:使用冻干机将步骤a中得到的牛脱细胞真皮基质冻干48h,使用粉碎机在30000r/min的转速下,将冻干后的牛脱细胞真皮基质打碎成粉末;
(2)牛脱细胞真皮基质溶液的制备:
将(1)中制备的牛脱细胞真皮基质粉末置于500mL含有3%(w/w)胃蛋白酶的0.2M乙酸溶液中室温消化24h,然后3000r/min离心10min取上清液,向上清液中加入5M的NaOH溶液调节pH至7左右;
(3)牛脱细胞真皮基质微球的制备:
向烧杯中加入1mL乳化剂span-80和100mL液体石蜡后混匀形成油相,置于搅拌器上,将(2)中的可溶性牛脱细胞真皮基质溶液加入油相中,室温下,200r/min搅拌1h形成水相/油相乳液。向乳液中加入200μL的10%戊二醛水溶液,搅拌1h,使牛脱细胞真皮基质固化。然后再向乳液中加入20mL异丙醇使油相和水相分层,3000r/min离心5min,去除上清液,将沉淀用丙酮、异丙醇和超纯水反复清洗3次后,置于PBS中浸泡过夜,去除PBS后得到牛脱细胞真皮基质微球。
实施例3
(1)犬骨髓间充质干细胞在牛脱细胞真皮基质微球上的三维培养
在制备的牛脱细胞真皮基质微球中接种犬骨髓间充质干细胞,在37℃、5%CO2培养箱中培养,2天后观察细胞生长状况。结果如图5所示,犬骨髓间充质干细胞可以在牛真皮脱细胞基质微球上生长。
(2)牛真皮脱细胞基质微球的细胞毒性检测
根据《GB/T16886.5-2017医疗器械生物学评价》,按照微球质量(g):完全培养基体积(mL)=1:5的比例提取微球浸提液。复苏犬骨髓间充质干细胞,待细胞达到80%-90%融合后,胰酶消化,终止消化后离心,细胞计数并加入完全培养基稀释。在无菌的96孔板的每孔添加100μL含有约4000细胞数犬骨髓间充质干细胞的完全培养基和牛脱细胞真皮基质微球的完全培养基浸提液。接种后的孔分为对照组和试验组,在细胞贴壁后,在试验组中添加微球浸提液代替培养基。连续培养5d,检测时,试验组和对照组换新完全培养基100μL,在每孔中添加10μL的CCK-8液,孵育2h,使用酶标仪测定490nm吸光光度值。结果见图6,对照组和试验组没有差异(P>0.05),证明牛脱细胞真皮基质微球没有细胞毒性。
(3)犬骨髓间充质干细胞培养接种于24孔板内,每孔1×105个细胞,并加入20mg微球,吹打混匀,平稳置入5%CO2、37℃培养箱静置培养,连续5d,每天检测一次。将微球吸入5mL离心管中,1000r/min室温离心5min,去除上清液,用PBS洗涤1-2遍,1000r/min室温离心5min,去除上清液。将Calcein AM与PI原液用工作液稀释1000倍后,每孔加入200μL,37℃避光孵育30min。孵育结束后,在荧光显微镜下观察染色效果。结果见图7,绿色荧光为活细胞,红色荧光为死细胞,犬骨髓间充质干细胞随天数的增加,活细胞数量也随之增加,但死细胞较少,说明制备的牛脱细胞真皮基质微球细胞相容性好,可用于犬骨髓间充质干细胞的三维培养。
(4)提取犬骨髓间充质干细胞在二维培养和三维培养中的总mRNA,反转录后,将配制好的RT-qPCR反应溶液置于荧光定量PCR仪上进行扩增反应。结果见图8,三维培养条件下,犬骨髓间充质干细胞表达的OCT4和SOX2与二维组相比,表达量显著上调(P<0.01),差异具有统计学意义。说明在牛脱细胞真皮基质微球上培养的犬骨髓间充质干细胞干性优于普通培养皿培养的犬骨髓间充质干细胞。
表1基因扩增引物
(5)使用ELISA试剂盒检测犬骨髓间充质干细胞在牛脱细胞真皮基质微球的三维培养条件下,细胞因子的分泌情况,结果见图9,三维培养下,TGF-β和EGF的分泌量都有极显著的上升(P<0.01),TSG-6和VEGF都有显著的上升(P<0.05)。
Claims (7)
1.一种牛脱细胞真皮基质微球,其特征在于,制备方法包括以下步骤:
(1)将牛皮去除表皮和脂肪组织后切成牛真皮小块,将牛真皮小块依次加入到碳酸钠溶液、NaCl溶液、SDS溶液中进行搅拌脱细胞处理,用水洗净后得到牛脱细胞真皮基质,然后将其冻干,粉碎,得到牛脱细胞真皮基质粉末;
(2)将牛脱细胞真皮基质粉末置于含有胃蛋白酶的乙酸溶液中消化24-48h,离心取上清液,用NaOH调节上清液pH至中性,得可溶性牛脱细胞真皮基质溶液;
(3)将乳化剂span-80和矿物油液体石蜡混匀形成油相,将可溶性牛脱细胞真皮基质溶液加入到油相中,搅拌形成乳液,然后向乳液中加入戊二醛使可溶性牛脱细胞真皮基质固化,最后向乳液中加入异丙醇使乳液分层,离心取沉淀,依次用丙酮、异丙醇和超纯水清洗,置于PBS中浸泡过夜,去除PBS后即得到牛脱细胞真皮基质微球。
2.如权利要求1所述的牛脱细胞真皮基质微球,其特征在于:所述碳酸钠溶液的浓度为1-10%,所述NaCl溶液的浓度为0.5-5M,所述SDS溶液的浓度为0.2-2%。
3.如权利要求1所述的牛脱细胞真皮基质微球,其特征在于:所述胃蛋白酶在乙酸溶液中的浓度为0.5-5%。
4.如权利要求1所述的牛脱细胞真皮基质微球,其特征在于:所述乙酸溶液的浓度为0.1-1M。
5.如权利要求1所述的牛脱细胞真皮基质微球,其特征在于:所述乳化剂与矿物油的体积比为1:50-100。
6.权利要求1-5任一项所述的牛脱细胞真皮基质微球在间充质干细胞三维培养中的应用。
7.如权利要求6所述的应用,其特征在于:所述牛脱细胞真皮基质微球为间充质干细胞提供天然的细胞外基质三维环境,提高间充质干细胞的细胞因子TGF-β、EGF、TSG-6和VEGF分泌功能和干性。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210866662.1A CN115161275B (zh) | 2022-07-22 | 2022-07-22 | 一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210866662.1A CN115161275B (zh) | 2022-07-22 | 2022-07-22 | 一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115161275A CN115161275A (zh) | 2022-10-11 |
CN115161275B true CN115161275B (zh) | 2024-03-19 |
Family
ID=83497717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210866662.1A Active CN115161275B (zh) | 2022-07-22 | 2022-07-22 | 一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115161275B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472870A (zh) * | 2020-12-03 | 2021-03-12 | 中国人民解放军陆军军医大学第一附属医院 | 一种人工微粒皮的制备方法及应用 |
CN114392395A (zh) * | 2022-01-11 | 2022-04-26 | 中国人民解放军军事科学院军事医学研究院 | 一种复合人间充质干细胞培养上清成分的脱细胞基质微粒及其制备方法与应用 |
CN114686421A (zh) * | 2022-04-18 | 2022-07-01 | 中山大学 | 一种肺组织脱细胞外基质微载体的制备方法及其应用 |
-
2022
- 2022-07-22 CN CN202210866662.1A patent/CN115161275B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472870A (zh) * | 2020-12-03 | 2021-03-12 | 中国人民解放军陆军军医大学第一附属医院 | 一种人工微粒皮的制备方法及应用 |
CN114392395A (zh) * | 2022-01-11 | 2022-04-26 | 中国人民解放军军事科学院军事医学研究院 | 一种复合人间充质干细胞培养上清成分的脱细胞基质微粒及其制备方法与应用 |
CN114686421A (zh) * | 2022-04-18 | 2022-07-01 | 中山大学 | 一种肺组织脱细胞外基质微载体的制备方法及其应用 |
Non-Patent Citations (1)
Title |
---|
Differentiation of mesenchymal stem cells into neuronal cells on fetal bovine acellular dermal matrix as a tissue engineered nerve scaffold;Feng Yuping 等;Neural Regeneration Research;20141115;第9卷(第22期);第 1968-197 8 页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115161275A (zh) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering | |
AU2010215506B2 (en) | Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies | |
US20030153078A1 (en) | Method for in vitro production of three-dimensional vital cartilage or bone tissue and use thereof as transplant material | |
CN102933705A (zh) | 去细胞化的脂肪组织 | |
US20180126037A1 (en) | Decellularized organ-derived tissue engineering scaffolds | |
KR19990022216A (ko) | 자연적으로 분비되는 세포외 매트릭스 조성물과 그 방법 | |
WO2012009958A1 (zh) | 用于体外大量扩增毛囊干细胞的培养方法 | |
CN101001652A (zh) | 生产皮肤替代物的交联胶原基质 | |
CN113846050B (zh) | 一种组织类器官的制备方法 | |
JP2014512232A (ja) | 細胞合成粒子 | |
CN103497892B (zh) | 一种细胞培养基材及其制备方法和应用 | |
CN107376025B (zh) | 一种用于软骨损伤修复的细胞-支架复合材料制备方法及应用 | |
KR100527623B1 (ko) | 세포외기질을 포함하는 인공장기 제조용 생분해성 고분자기질 및 그의 제조방법 | |
CN115161275B (zh) | 一种牛脱细胞真皮基质微球及其在细胞三维培养中的应用 | |
CN101195044A (zh) | 一种组织工程化微粒组织及其制备方法 | |
CN109112101A (zh) | 一种成纤维细胞培养基及其应用 | |
CN114686421B (zh) | 一种肺组织脱细胞外基质微载体的制备方法及其应用 | |
CN103874763A (zh) | 从胎儿组织制备亲代细胞库 | |
Zhao et al. | In vitro study of bioactivity of homemade tissue-engineered periosteum | |
CN104877954A (zh) | 一种干细胞壁龛及其制备方法与应用 | |
KR20210103984A (ko) | 심장 오가노이드 배양 및 이식을 위한 탈세포 심장 조직 유래 지지체 및 이의 제조방법 | |
CN102475913A (zh) | 一种通过组织工程构建的瓣膜组织 | |
CN111793601A (zh) | 一种载纤连蛋白多孔支架增加干细胞体内留存时间的方法 | |
CN100482784C (zh) | 诱导成纤维细胞形成软骨细胞的方法 | |
KR102578904B1 (ko) | 위 오가노이드 배양 및 이식을 위한 탈세포 위 조직 유래 지지체 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |